On looking to a future multiomics approach for CDx, with Jane Li

Oncology
pharmaphorum podcast Episode 287, Jane Li, Thermo Fisher Scientific

Slow companion diagnostic adoption delays patient access to targeted therapies, particularly in regional and community hospital settings.

In a new pharmaphorum podcast, Nicole Raleigh caught up with Jane Li, vice president and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.

Li discusses what it takes for a companion diagnostic (CDx) to be ready on the day a targeted therapy reaches patients, and the barriers between diagnostic innovation and routine clinical use, as well as her key takeaways from the oncology congress.

You can listen to episode 287 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.